MEDISTEP
MEDISTEP financials
- Market cap
- ₹32 Cr
- Sector
- Fast Moving Consumer Goods
Quarterly results
| Line item | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|
| Revenue | 21 | 28 | 35 | 36 |
| EBITDA | 2 | 3 | 4 | 4 |
| Net profit | 2 | 2 | 3 | 3 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −31.4% 1Y
1Y: ₹31.35 on 15 Sept 2025 → ₹21.5. High ₹33.5 (17 Sept 2025), low ₹16.5 (30 Mar 2026).
Balance sheet
| Year ending | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | ₹5 Cr | ₹10 Cr | ₹14 Cr |
| Reserves | ₹7 Cr | ₹7 Cr | ₹24 Cr |
| Borrowings | ₹0 Cr | ₹1 Cr | ₹5 Cr |
| Other liabilities | ₹3 Cr | ₹5 Cr | ₹7 Cr |
| Total liabilities | ₹15 Cr | ₹23 Cr | ₹50 Cr |
| Fixed assets | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹15 Cr | ₹23 Cr | ₹50 Cr |
| Total assets | ₹15 Cr | ₹23 Cr | ₹50 Cr |
How to read this
As filed on each reporting date, including interim balance sheets. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
The ownership split has held steady since Sep 2025. The shareholder count shrank 11% to 514.
- Promoters
- 69.0%
- Public
- 31.0%
Since Sep 2025
- Promoters 0.00 pp
- Public 0.00 pp
Who bought this quarter
since Sep 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Babitha Menon newly disclosed 1.79% held
- Vijith Narayanan Menon +0.74 pp 2.60% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of MEDISTEP above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Prajapati Hetalben Shankarlal | 50.08% | unchanged |
| Girdharilal Prajapat | 9.94% | unchanged |
| Vipul Gobarbhai Dabhi | 8.94% | unchanged |
| Nitin Singh Bhati | 4.69% | unchanged |
| Vijith Narayanan Menon | 2.60% | +0.74 pp |
| Tirulekha Biosciences Private Limited | 1.94% | −0.11 pp |
| Babitha Menon | 1.79% | newly disclosed |
| Dharmishthaben Vipulbhai Dabhi | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- -22.8% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
Learn to analyse MEDISTEP
Guides on how to read this kind of business and the numbers that matter.